Our conference for this year has now sold out so apologies for anybody who is unable to attend. We will publish the presentations later this year on the website and remember to book early for next year CLOT Committee
The Atrial Fibrillation Stroke Prevention Team comprising Dr Indira Natarajan, Claire Moss and CLOT secretary Jodie Williams won the team award in the Excellence in Patient Care Awards 2016 at the Royal College of Physicians award ceremony in Harrogate. The judges said " The AF stroke prevention team tackled a common problem which can often be managed poorly. The project shows great integration between primary and secondary care involving patients throughout. It demonstrates a multi-professional approach that clearly shows excellent outcomes demonstrating clinical efficacy". Well done Jodie from all at CLOT
We are aware there has been an issue with activation emails not being received when new registrations have been made. This problem has now been resolved and we have contacted most people who registered but could not activate their accounts. If you are still having problems either try registering again or contact us to do this manually. Really Sorry for any problems caused. Huw Website Editor
The first CLOT session at the British Society of Haematology Annual Scientific Meeting was held on the 19th April 2016 and featured presentations on real world data on the use of DOAC's, how long to anticoagulate post unprovoked VTE, a comparison of risk factors for community and hospital acquired thrombosis with a five year follow up looking at recurrence and mortality and limited vs whole leg scanning. The session proved very popular as we not only filled the room we were using but also an overflow room next door. We are hopeful that we will be invited back to present at next years meeting in Brighton in March 2017 and should know before our annual meeting.
Praxbind® (idarucizumab) licensed in European Union for the specific reversal of Pradaxa® (dabigatran etexilate)
- Idarucizumab is the first specific reversal agent for a NOAC to receive European licence1
- Idarucizumab immediately reverses the anticoagulant effect of dabigatran2-4
Bracknell, United Kingdom - 26th November 2015 – The European Commission has licensed Praxbind® (idarucizumab), a treatment to rapidly and specifically reverse the anticoagulant effects of Pradaxa® (dabigatran etexilate) in cases of emergency surgery /urgent procedures or in situations of life-threatening or uncontrolled bleeding.1 Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant (NOAC) to be granted a licence in the European Union.1